Log in | Join Free | china | japan | germany
ChemicalBook > Product Catalog >API >Other Chemical drugs >2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-

2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-

Request For Quotation
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Basic information
Product Name:2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-
Synonyms:2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-
CAS:2448172-10-7
MF:C32H34N8O3
MW:578.67
EINECS:
Product Categories:
Mol File:2448172-10-7.mol
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Structure
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Chemical Properties
density 1.39±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
pka11.83±0.20(predicted)
Safety Information
MSDS Information
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Usage And Synthesis
DescriptionBMF-219 is the first and only covalent menin inhibitor in clinical development and is being evaluated in multiple hematologic malignancies, solid tumours, and diabetes mellitus. COVALENT-101 (NCT05153330) is a Phase I dose-escalation and -expansion study of BMF-219 in R/R AL, DLBCL, MM, and CLL.
UsesBMF-219 is a covalently binding inhibitor of menin, a protein that plays an essential role in oncogenic signaling in genetically defined leukemias and diabetes. Preclinically, BMF-219 has demonstrated in well-established acute leukemia cell lines robust downregulation of essential leukemogenic genes in addition to menin itself. Additionally, BMF-219 has shown anticancer activity in multiple in vitro, in vivo, and ex vivo models of acute leukemia, multiple myeloma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. BMF-219 is currently being evaluated in first-in-human clinical trials enrolling patients with specific menin-dependent mutations in liquid and solid tumours and patients with diabetes.
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Preparation Products And Raw materials
Tag:2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-(2448172-10-7) Related Product Information